Business Context and Reporting Period
This Form 8-K is a current report filed by PharmAthene, Inc. (not Altimmune, Inc.) on September 22, 2011. The filing reports corporate governance changes effective as of that date.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a board appointment and associated compensation.
Material Changes
- Board Appointment: Brian A. Markison was appointed to the Board of Directors effective September 22, 2011.
- Compensation Grant: Mr. Markison received a stock option to purchase 20,000 shares of common stock.
- Option Terms: The exercise price is $2.74 per share (closing price on NYSE Amex on September 22, 2011). The option vested immediately and expires on September 22, 2021.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding financial guidance, future outlook, risks, contingencies, or unusual items. It references a press release dated September 26, 2011, attached as Exhibit 99.1, but the content of that release is not included in the provided text.
Investor Verification Checklist
- Verify the identity of the registrant (PharmAthene, Inc.) versus the requested company name (Altimmune, Inc.).
- Confirm the vesting schedule and expiration date of the 20,000 share option granted to Brian A. Markison.
- Review the attached press release (Exhibit 99.1) for additional context on the appointment.